Physician profile
Mark Riederman
NPI 1699782151
$10,558.48
in general payments reported to CMS, 2019-2025
44 companies · $1,415 in 2025
The $1,415 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,939 · 2020: $1,731 · 2021: $1,342 · 2022: $966 · 2023: $1,199 · 2024: $1,968 · 2025: $1,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,580.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,285.40 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $1,147.86 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $1,110.97 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,083.93 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $791.19 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $752.62 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $714.83 | 2019-2025 | |
| Glaxosmithkline, LLC. | $431.51 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $415.02 | 2019-2025 | Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $395.28 | 2019-2024 | Spravato |
| Sanofi Pasteur INC. | $319.25 | 2019-2025 | |
| Allergan, INC. | $219.66 | 2019-2020 | |
| Edwards Lifesciences Corporation | $203.55 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Exact Sciences Corporation | $153.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $147.42 | 2019-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Riederman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.